Synonyms: GI-7977 | PSI 7977 | Sovaldi®
sofosbuvir is an approved drug (FDA (2013), EMA (2014))
Compound class:
Synthetic organic
Comment: Sofosbuvir is a nucleotide analogue whose action inhibits hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase. It acts as a chain terminator to limit viral RNA replication.
Sofosbuvir is on the World Health Organisation's List of Essential Medicines. Click here to access the pdf version of the WHO's 21st Essential Medicines list (2019). |
|
No information available. |
Summary of Clinical Use ![]() |
Used in combination therapy to treat hepatitis C viral infection with or without co-infection with HIV. |
Mechanism Of Action and Pharmacodynamic Effects ![]() |
Prevents HCV viral replication by inhibiting HCV NS5B polymerase. |
External links ![]() |
For extended ADME data see the following: Electronic Medicines Compendium (eMC) Drugs.com European Medicines Agency (EMA) |